Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Endogenous Metabolite
    (4)
  • PDE
    (4)
  • Glucagon Receptor
    (1)
TargetMol | Tags By ResearchField
  • Endocrine system
    (4)
  • Inflammation
    (4)
  • Metabolism
    (4)
  • Nervous System
    (3)
  • Reproductive system
    (1)
Filter
Search Result
Results for "

zucker diabetic fatty rats

" in TargetMol Product Catalog.
  • Inhibitors & Agonists
    5
    TargetMol | All_Pathways
  • Peptide Products
    1
    TargetMol | Peptide_Products
  • Vardenafil dihydrochloride
    Vardenafil Hydrochloride, Levitra
    T4480224789-15-5
    Vardenafil dihydrochloride (Levitra) is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.
    • $46
    Inquiry
    Size
    QTY
  • Vardenafil
    Vivanza, Levitra
    T0096224785-90-4
    Vardenafil (Vivanza) is an oral therapy for the treatment of erectile dysfunction. It is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). Penile erection is a hemodynamic process initiated by the relaxation of smooth muscle in the corpus cavernosum and its associated arterioles. During sexual stimulation, nitric oxide is released from nerve endings and endothelial cells in the corpus cavernosum. Nitric oxide activates the enzyme guanylate cyclase resulting in increased synthesis of cyclic guanosine monophosphate (cGMP) in the smooth muscle cells of the corpus cavernosum. The cGMP in turn triggers smooth muscle relaxation, allowing increased blood flow into the penis, resulting in erection. The tissue concentration of cGMP is regulated by both the rates of synthesis and degradation via phosphodiesterases (PDEs). The most abundant PDE in the human corpus cavernosum is the cGMPspecific phosphodiesterase type 5 (PDE5); therefore, the inhibition of PDE5 enhances erectile function by increasing the amount of cGMP.
    • $31
    In Stock
    Size
    QTY
  • Vardenafil hydrochloride trihydrate
    Vardenafil HCl Trihydrate, BAY38-9456
    T4097330808-88-3
    Vardenafil hydrochloride trihydrate (BAY38-9456) is a new type PDE inhibitor with IC50 of 0.7 and 180 nM for PDE5 and PDE1, respectively.
    • $33
    In Stock
    Size
    QTY
  • Vardenafil hydrochloride
    T8405224785-91-5
    Vardenafil hydrochloride is a New Phosphodiesterase Type 5(PDE5) Inhibitor, in the Treatment of Erectile Dysfunction in Men With Diabetes
    • $30
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Taspoglutide acetate
    BIM-51077C, [Aib8,35]hGLP-1(7-36)NH2
    TP29061022150-16-8
    Taspoglutide, acting as an agonist for the glucagon-like peptide-1 receptor (GLP-1R; Ki = 1.1 nM for the human receptor), induces cAMP accumulation in CHO-K1 cells expressing human GLP-1R (EC50 = 0.06 nM). In oral glucose tolerance tests conducted on Zucker diabetic fatty rats, Taspoglutide (administered weekly at 1 mg/animal) significantly reduced blood glucose levels and increased insulin levels. Additionally, in the same model, it also lowered blood levels of gastric inhibitory polypeptide (GIP), plasma triglycerides, and body weight.
    • Inquiry Price
    Inquiry
    Size
    QTY